Research and Markets (http://www.researchandmarkets.com/research/da1942/pharmaceutical_com) has announced the addition of the "Pharmaceutical Company Outlook to 2014" report to their offering.
PharmaVitae universe Rx sales are forecast to expand at a 2008-14 CAGR of 1.2%, down 9.3 percentage points from 2002-08. The underlying cause of this falling rate is the much-discussed genericization of small molecule products. However, not all sectors are equally exposed, prompting a shake-up of the industry and an increasing pursuit of cost savings to sustain operating profit growth rates.
Scope
- Analysis of the sales outlook for the PharmaVitae universe of leading prescription pharma companies to 2014
- Assessment of the impact of future launches and patent expiries on sales growth compared to historical trends
- Segmentation of the market by therapy area and molecule type to assess high- and low-growth sectors of the industry
- Assessment of the impact of cost-cutting on operating profit growth in an environment of low and sometimes negative sales growth
Highlights of this title
The increasing assault of generics on leading pharma players' staple diet of small molecule products will prompt a shake-up of the industry. Companies' success will be heavily linked to their exposure to this generic threat, with biologics and niche players enjoying the greatest insulation and therefore often the highest growth.